Zydus Lifesciences Ltd
NSE: ZYDUSLIFE BSE: 532321
₹902
(2.54)%
Tue, 03 Feb 2026, 08:30 am
Market Cap890.72B
PE Ratio18.45
Dividend1.24
Health Technology
Pharmaceuticals: Major
24.5Kzydus lifesciences ltd History
1995
- Incorporated as Cadila Healthcare Private Ltd. on May 15.
- Signed agreement with Anda Biologicals, France, for diagnostic kits marketing.
1996
- Converted to public company and renamed Cadila Healthcare Ltd. effective July 17.
- Signed agreement with Centeon for plasma products rights in India and Nepal.
- Signed agreement with Acta Services for Acto 1 Analyser distribution.
- Signed agreement with China Resources Gulin Pharma for Artesunate Granules.
- Signed agreement with Shimizu Chemical Corporation for product marketing.
1997
- High Court of Gujarat sanctioned Scheme of Arrangement and Amalgamation.
- Issued 1,48,423 equity shares to Patel Group shareholders.
- Tied up with Regional Research Laboratory Jammu for Paroxetine HCL enzymatic resolution.
1998
- Signed agreement with Apotex SA Pty. Ltd. for manufacturing Amoxycillin, Ampicillin, Co-trimoxazole, and Paracetamol.
- Entered JV with Korea Green Cross Corporation for recombinant Hepatitis B vaccine.
1999
- Signed agreement with Ethical Holdings for transdermal formulations.
- Signed agreement with Cherry Valley Farms for vaccine eggs.
- Entered 50:50 JV with Byk Gulden for Pantoprazole.
- Issued 2,00,000 12% Cumulative Redeemable Preference shares.
- Indon Healthcare Limited and Zydus Aqrovet Limited became wholly owned subsidiaries.
- Planned Losartan manufacturing project at Ankleshwar.
- Laid foundation for feed supplement plant at Vatwa.
- Entered technical tie-up with Swiss Serum and Vaccine Institute for vaccines.
- Entered JV with Haffkine Institute for human vaccines and equine sera.
- Began setting up R&D centre at Moraiya for Rs. 25 crores.
- Launched Vac Typh, HB Vac, Xylodac, Losartan, and Matergam P.
- Set up manufacturing for Improval at GIDC Vatwa.
- Pranlal Bhogilal appointed additional Director on December 15.
- Introduced new employee welfare policy.
2000
- Company planned wholly owned subsidiaries abroad.
- Entered license agreement with Swiss Serum and Vaccine Institute for Purified Chick Embryo Vaccine.
- Launched two HIV drugs.
- Ankleshwar Bulk Drugs received ISO 9002 certification.
- Public issue of 1,48,86,000 equity shares.
- Authorised share capital increased to Rs 500 million.
- Recognized as Prestigious Unit for sales tax deferment.
- Zydus Pharmaceuticals Limited and Zoom Properties Limited became wholly owned subsidiaries.
- Formed Zydus Byk Healthcare JV with Byk Gulden.
- Formed Sarabhai Zydus Animal Health JV with Ambalal Sarabhai Enterprises.
- Launched Atorvastatin, Lamivudine, Celecoxib, Meloxicam, and Carvedilol.
- Acquired Recon Limited brands; Recon Healthcare Ltd. became subsidiary.
- Launched zidovudine as Zydowin.
- Launched www.penegra.org.
- Completed phase-III trials and bioequivalence study for sildenafil citrate.
2001
- Cadila Healthcare signed three-year R&D agreement with Pantheco for anti-bacterials.
- Neurosciences division launched paroxetine first in India.
2002
- Board approved issuance of Rs 700 million Secured Redeemable Non Convertible Debentures.
2003
- Upen Shah designated as Company Secretary.
- Zydus Cadila bagged global marketing rights for Vaxirab anti-rabies vaccine.
- Cadila Healthcare received Mumbai High Court approval for amalgamation with German Remedies Ltd. and Zoom Properties Ltd.
- Cadila Healthcare acquired Alpharma SAS France for Euro 5.5 million.
- H.K. Bilpodiwala, H. Dhanarajgir, and A.S. Diwanji appointed as additional directors.
- Zydus Cadila signed pact with Schering AG for patented products in India.
2004
- Zydus Cadila set up Zydus Pharmaceuticals USA, Inc.
- Zydus Cadila inked strategic pact with Boehringer Ingelheim.
- Zydus Altana Healthcare JV received ISO 9001-2000 accreditation.
2005
- Zydus Cadila received USFDA approval for Atenolol and Clindamycin.
- Zydus Cadila unveiled Pitavastatin.
- Cadila tied up with Tyco unit for generic drugs in US.
- Cadila Healthcare launched NuPatch Diclofenac transdermal patch.
- Cadila Healthcare and Mayne signed agreement for oncology JVC.
- Cadila Healthcare launched Fludara Oral.
- Zydus Cadila received tentative USFDA approval for Divalproex Sodium DR Tablets.
- Cadila Healthcare received USFDA approval for Promethazine Tablets.
- Cadila Healthcare entered JV with BSVL.
2006
- Zydus Cadila forged alliance with French firm.
- Zydus Cadila received USFDA approval for Simvastatin Tablets.
- Zydus Cadila planned to acquire Nutralite.
- Sarabhai Zydus planned to roll out immuno-diagnostics kits.
- Cadila Healthcare issued 1:1 bonus.
2007
- Cadila Healthcare acquired Nippon Universal Pharmaceutical Ltd.
- Cadila Healthcare acquired Quimica e Farmaceutica Nikkho do Brasil Ltda.
- Zydus Cadila launched anti-obesity drug Slimona first in India.
2008
- Zydus Cadila and Karo Bio signed research agreement for inflammatory disease drug.
- Zydus Cadila acquired Etna Biotech from Crucell N.V.
- Zydus Cadila launched Venlafaxine Hydrochloride in US on first day.
2009
- Zydus Cadila announced research collaboration for cardiovascular medicines.
- Zydus Research Centre received AAALAC Accreditation.
2010
- CHL announced bonus shares in 1:2 ratio.
- Cadila Healthcare developed and launched India's first indigenous H1N1 vaccine.
2011
- Company signed agreement with Bayer HealthCare for 50:50 JV Bayer Zydus Pharma.
- Cadila received USFDA nod for diabetes drug trial.
- Cadila Health acquired Bremer Pharma from ICICI Venture.
2012
- Cadila Healthcare entered settlement and license agreement with Somaxon for Silenor.
- Cadila Healthcare received USFDA approval for Aripiprazole orally disintegrating tablets.
2013
- Zydus Cadila received tentative USFDA approval for Doxepin HCl tablets.
- Zydus and IDRI signed agreement for Visceral Leishmaniasis vaccine candidate.
- Zydus and Pieris signed broad co-development alliance for Anticalin therapeutics.
- Zydus Pharmaceuticals (USA) Inc. signed agreement with Warner Chilcott Company LLC.
2014
- Zydus and Gilead entered generic licensing agreement for Hepatitis C treatment.
- Zydus launched world’s first biosimilar of Adalimumab.
- Cadila Healthcare launched Lipaglyn, India's first NCE.
2015
- Zydus Cadila completed single ascending dose study.
- Zydus launched SoviHep for Hepatitis C in alliance with Gilead Sciences.
- Cadila Healthcare purchased remaining 50% shares of Zydus BSV Pharma.
- Cadila Healthcare received final USFDA approval for Pyridostigmine Bromide Tablets.
- Cadila Healthcare received USFDA market authorisation for chronic pain drug.
- Cadila Healthcare received final USFDA approval for Amiloride Hydrochloride Tablets.
- Zydus launched Tenglyn gliptin.
- Cadila Healthcare split face value from Rs. 5 to Rs. 1.
2016
- Zydus Cadila acquired select animal health brands from Zoetis.
- Zydus received final USFDA approval for Glyburide and Metformin HCl Tablets.
- Zydus acquired gastro therapy Actibile from Albert David Limited.
- Zydus received USFDA approval for Glyburide Tablets.
- Zydus acquired two ANDAs from Teva.
- Zydus acquired six brands from MSD.
2017
- Zydus received final USFDA approval for Temozolomide Capsules and Nadolol Tablets.
- Zydus Cadila acquired Sentynl Therapeutics Inc.
- Zydus and Pharm Aid Ltd. entered exclusive agreement for vaccine technology in Russia.
- Zydus received EIR for manufacturing facility at Pharma SEZ Ahmedabad.
- Zydus received final USFDA approval for Desvenlafaxine Extended-Release Tablets.
- Cadila Healthcare entered agreement with Phibro Animal Health for poultry vaccine technologies.
2018
- Zydus Cadila received USFDA approval for sedative injection.
- Zydus entered agreement with Medicure International for pitavastatin NDA in US.
- Zydus Cadila received USFDA approval for Omeprazole and Sodium Bicarbonate Capsules.
- Zydus Cadila received approval for Carbidopa Tablets.
- CSIR-IMTECH inked pact with Zydus Cadila.
- Zydus Cadila launched generic erectile dysfunction drug in US.
2019
- Zydus launched Ramelteon Tablets for insomnia.
- Zydus received tentative USFDA approval for Lorcaserin Hydrochloride Tablets.
2020
- Zydus and CMS entered pact for Desidustat in Greater China.
- Zydus Wellness launched hand sanitizer under Nycil brand.
- Zydus Cadila launched COVID-19 drug Remdesivir in India.
- Zydus Cadila launched new product for COPD patients in India.
2021
- Zydus Cadila launched Trastuzumab Emtansine under brand Ujvira.
- Cadila Healthcare received orphan drug designation for malaria treatment compound.
2022
- Zydus Life received USFDA final approvals for Silodosin and Pregabalin.
- Zydus Group had 338 approvals and filed over 431 ANDAs.
- Zydus Life received final USFDA approval for Topiramate extended-release capsules.
- Zydus Lifesciences' arm received EC approval for MoCD injection.
- Received Pharma Company of the Year Award, Excellence in CSR, and 7th India Pharma CSR award.
2023
- Zydus Lifesciences inked licensing pact with Daewoong Pharmaceutical.
- Zydus Lifesciences received USFDA approval for Acyclovir Cream.
- Sentynl Therapeutics completed asset transfer of CUTX-101 from Cyprium Therapeutics.
- Zydus Lifesciences received 7th CSR Health Impact Award.
2024
- Zydus Lifesciences received WHO prequalification for Typhoid Vi conjugate vaccine.
- Zydus Lifesciences received Mexican regulatory approval for cancer treatment biosimilar.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800